The Correlation and Mechanistic Study of GGCX Gene With Prognosis in Acute Ischemic Stroke

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

1500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2026-01-25

Study Completion Date

2028-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This observational study aims to investigate the impact of GGCX gene mutations and GGCX levels on stroke prognosis in patients with ischemic stroke, as well as their correlation. The main issues are:

What is the relationship and potential mechanism between GGCX gene mutations and their expression levels and the composite prognosis of recurrence, death, and bleeding events in patients with ischemic stroke? Collect blood samples from enrolled ischemic stroke patients for genetic testing, and conduct follow-up visits at 3, 6, and 12 months after discharge to evaluate clinical prognosis outcomes. This will answer questions about the relationship and mechanism between GGCX gene and patient prognosis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Early Neurological Trajectory and Clinical Outcomes in Brain Acute Ischemic Stroke

NCT06170086

Stroke, Acute

ACTIVE_NOT_RECRUITING

Prognosis in Subacute Ischemic Stroke Using Multimodal Imaging

NCT06289036

The Levels of Cerebral Perfusion and Collateral Circulation in Patients With Subacute Stroke

COMPLETED

Which Parameters of Short-term Blood Pressure Variability Best Predict Early Outcomes in Acute Ischemic Stroke

NCT02675972

Stroke

COMPLETED

Clinical Research of Intravenous Thrombolysis for Ischemic Stroke in Northeast of China

NCT05028868

Ischemic Stroke Thrombosis

RECRUITING

Prospective Cohort of Patients With Intracerebral Hemorrhage

NCT06670456

Stroke, Acute Intracerebral Hemorrhage

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Ischemic Stroke

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Acute Ischemic Stroke Group

These subjects were acute ischemic stroke patients who had been followed up for 3-12 months after discharge.

Usually, all enrolled patients with acute ischemic stroke will receive routine medication and/or surgical treatment according to clinical diagnosis and treatment protocols.

Intervention Type COMBINATION_PRODUCT

The conventional drug therapy includes anticoagulant, antiplatelet, antihypertensive and other drugs. The surgical therapy includes AIS intravenous thrombolysis or endovascular therapy.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Usually, all enrolled patients with acute ischemic stroke will receive routine medication and/or surgical treatment according to clinical diagnosis and treatment protocols.

The conventional drug therapy includes anticoagulant, antiplatelet, antihypertensive and other drugs. The surgical therapy includes AIS intravenous thrombolysis or endovascular therapy.

Intervention Type COMBINATION_PRODUCT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Aged between 18 and 85 years.
2. Diagnosed with ischemic stroke (in accordance with the "Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke 2023," including TOAST etiological/pathogenic subtypes: large-artery atherosclerosis (LAA), cardioembolism (CE), small-artery occlusion (SAO), stroke of other determined etiology (SOE), and stroke of undetermined etiology (SUE)).
3. Acute onset, with symptoms occurring within 72 hours and being the first episode.
4. Voluntary participation with signed informed consent.

Exclusion Criteria

1. Patients with cerebrovascular diseases occurring within 72 hours.
2. Pregnant or lactating patients.

1. Other types of stroke, including hemorrhagic stroke, mixed stroke, and tumor-related stroke patients.
2. Patients with coagulation disorders or other hematologic diseases.
3. Patients with severe cardiovascular, pulmonary, or hepatic diseases.
4. Renal dysfunction.
5. Cancer patients.
6. Patients with active gastric ulcers or gastric bleeding.
7. Pregnant or lactating patients.

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes